IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

BORGHI, MARIA ORIETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.946
NA - Nord America 3.699
AS - Asia 2.016
SA - Sud America 119
OC - Oceania 21
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.820
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.422
GB - Regno Unito 1.478
CN - Cina 1.031
DE - Germania 936
IT - Italia 734
SE - Svezia 495
ES - Italia 273
CA - Canada 232
SG - Singapore 215
FR - Francia 198
IE - Irlanda 162
IN - India 157
TR - Turchia 149
KR - Corea 130
UA - Ucraina 130
FI - Finlandia 106
HK - Hong Kong 106
JP - Giappone 83
NL - Olanda 75
RU - Federazione Russa 73
EU - Europa 63
VN - Vietnam 61
BE - Belgio 51
DK - Danimarca 49
CO - Colombia 47
GR - Grecia 44
MX - Messico 40
BR - Brasile 38
ID - Indonesia 38
CH - Svizzera 36
PT - Portogallo 20
AU - Australia 19
AR - Argentina 15
PL - Polonia 14
TW - Taiwan 11
PE - Perù 9
RO - Romania 9
AT - Austria 8
CZ - Repubblica Ceca 8
HU - Ungheria 8
CL - Cile 6
IR - Iran 6
NO - Norvegia 6
RS - Serbia 6
SC - Seychelles 6
BY - Bielorussia 5
IL - Israele 5
PH - Filippine 5
SK - Slovacchia (Repubblica Slovacca) 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
CU - Cuba 3
EG - Egitto 3
IQ - Iraq 3
LU - Lussemburgo 3
PK - Pakistan 3
CR - Costa Rica 2
HR - Croazia 2
LB - Libano 2
LT - Lituania 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
TN - Tunisia 2
UY - Uruguay 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BG - Bulgaria 1
BT - Bhutan 1
CY - Cipro 1
JO - Giordania 1
KE - Kenya 1
ME - Montenegro 1
MU - Mauritius 1
QA - Qatar 1
SA - Arabia Saudita 1
SI - Slovenia 1
Totale 10.882
Salva come PNG Salva come JPEG
Città #
Southend 1.307
Chandler 536
Hanover 372
Milan 250
Seattle 230
Beijing 224
Princeton 216
Wilmington 190
Dublin 160
Fairfield 154
Ashburn 150
Ann Arbor 143
Hangzhou 133
Montréal 110
Dearborn 109
Munich 108
Nanjing 91
Woodbridge 90
Frankfurt am Main 88
Singapore 88
Mcallen 87
Toronto 79
Houston 75
Hong Kong 74
Redmond 70
Des Moines 69
Jacksonville 67
Phoenix 67
Mountain View 66
Bengaluru 64
Grafing 63
Shanghai 58
Cambridge 55
Redwood City 54
Sakarya 47
Boardman 46
Madrid 45
Helsinki 41
Serra 41
Somerville 41
Jinan 40
Dong Ket 39
Bogotá 38
Brussels 37
New York 37
Granada 36
Andover 35
Berlin 33
Barcelona 32
Tokyo 32
Guangzhou 30
Falls Church 25
Shenyang 25
Athens 24
Seoul 24
Sunnyvale 23
Changsha 22
Hebei 22
Jakarta 22
Los Angeles 22
Paris 21
Fremont 20
Hamburg 19
San Diego 19
Tianjin 19
Eitensheim 18
Zhengzhou 18
Córdoba 17
Istanbul 17
Jiaxing 16
Duncan 15
Ottawa 15
Taiyuan 14
Boston 13
Chicago 13
Nanchang 13
Washington 13
Haikou 12
London 12
Harbin 11
Pisa 11
Las Palmas de Gran Canaria 10
Mumbai 10
Osaka 10
Silver Spring 10
Central 9
Medford 9
Norwalk 9
Verona 9
Bitonto 8
Brooklyn 8
Central District 8
Hefei 8
Kent 8
Lima 8
Mexico City 8
Pittsburgh 8
Porto Alegre 8
São Paulo 8
Brest 7
Totale 7.045
Salva come PNG Salva come JPEG
Nome #
Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases 1.476
Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications 471
Complement activation in anti-phospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery 380
Role of epigenetic therapy in the modulation of tumor growth and migration in human castration-resistant prostate cancer cells with neuroendocrine differentiation 301
Antiphospholipid Antibodies and Infertility : A Gene Expression Study in Decidual Stromal Cells 257
Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts 226
Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid syndrome 210
L’aumento del drive simpatico che si osserva durante bypass aortocoronarico correla con l’espressione delle citochine proinfiammatorie ed é attenuato dalla terapia betabloccante 189
Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines 180
8-Chloro-cyclic AMP and protein kinase A I-selective cyclic AMP analogs inhibit cancer cell growth through different mechanisms 173
Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants 159
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers 159
Protective effect of a synthetic peptide mimicking the b2GPI PL-binding site on aPL-induced placental damage 157
Complement activation and endothelial perturbation parallel COVID-19 severity and activity 147
TLR-4 and Annexin A2 Involvement in endothelial cell activation by anti-phospholipid antibodies : specific silencing by small interfering RNAs 139
Anti-phospholipid antibody mediated fetal loss : still an open question from a pathogenic point of view 133
Association between clinical features and inflammatory gene SNPs in APS 132
Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus 130
Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. 126
Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss 121
Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts 121
Patients with antiphospholipid syndrome display endothelial perturbation 118
Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus 117
Anti-NR2 antibodies and primary antiphospholipid syndrome : a preliminary study 116
Antiphospholipid antibodies and ex-vivo endothelial perturbation 113
Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis : report of a family with multiple anti-phospholipid positive members 113
Antiphospholipid antibodies and the antiphospholipid syndrome : pathogenic mechanisms 113
Mechanisms of action of antiphospholipid antibodies 112
8-Cl-cAMP and PKA I-selective cAMP analogs effectively inhibit undifferentiated thyroid cancer cell growth 110
Toll-like receptor and antiphospholipid mediated thrombosis : in vivo studies 109
Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation 105
Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy 105
Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation 104
Humoral autoimmunity against endothelium : theory or reality? 103
Toll-like receptors : another player in the pathogenesis of the anti-phospholipid sindrome 102
Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement 101
Endothelium activation in the anti-phospholipid syndrome 99
Antibodies Against Domain 1 and Domain 4/5 of β2 Glycoprotein I : Clinical Relevance in Obstetric Anti-Phospholipid Syndrome 98
Pathogenesis of antiphospholipid syndrome : understanding the antibodies 95
Effect of TNFalpha blocking agents on mRNA and miRNA profile in RA patients 94
Relationship between sle susceptibility genes and clinical manifestations in a cohort of patients with primary antiphospholipid syndrome 93
Role of anti-beta(2) glycoprotein I antibodies in anti phospholipid syndrome : In vitro and in vivo studies 92
Anti-fibroblast antibodies in systemic sclerosis 91
Antiphospholipid syndrome: not only an antibody-mediated disease 90
TLR-4 and Annexin A2 involvement in pathogenic effects induced by anti-phospholipid antibodies is demonstrated by specific blocking agents and small interfering RNA in human endothelial cells 89
Beta2-glycoprotein I as a 'cofactor' for anti-phospholipid reactivity with endothelial cells 89
Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome 88
Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis 87
The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines 85
Interferon-inducible genes, TNF-related apoptosis-inducing ligand (TRAIL) and interferon inducible protein 27 (IFI27) are negatively regulated in leiomyomas: implications for a role of the interferon pathway in leiomyoma development 84
Innate immunity in the antiphospholipid syndrome : role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies 83
Endothelial cell activation by antiphospholipid antibodies 83
Complement activation in anti-phospholipid syndrome : a clue for an inflammatory process? 83
The Efficacy of Treatment with Low Dose Aspirin and Low Molecular Weight Heparin in Pregnant Women with Criteria Anti-Phospholipid Antibodies 82
Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block : lesson from twins and triplets discordant for the disease 80
Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2-glycoprotein i domain 1 and domain 4/5 : ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome 80
Early endothelial damage in patients with raynaud's phenomenon 80
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy 80
Empirical Approach to Investigate Raynaud's Phenomenon : the Pearl Study : AB1085  79
In vivo effects of maternal immunosuppression during pregnancy on the immune function of newborn infants. 78
Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro 78
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors 77
Immunopharmacological activity of cefodizime in young and elderly subjects: in vitro and ex vivo studies. 76
Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies 76
Immune parameters identify Italian centenarians with a longer five-year survival independent of their health and functional status 73
Vandetanib versus cabozantinib in medullary thyroid carcinoma: A focus on anti‐angiogenic effects in zebrafish model 72
European forum on antiphospholipid antibodies : research in progress 71
Differential impairment of serum cholesterol efflux capacity in patients with rheumatoid arthritis and systemic lupus erythematosus 71
Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome 67
Antibodies and Diagnostic Tests in Antiphospholipid Syndrome 64
Production of anti-{PF}4 antibodies in antiphospholipid antibody-positive patients is not affected by {COVID}-19 vaccination 64
Histone deacetylase inhibitors ameliorate morphological defects and hypoexcitability of iPSC-neurons from Rubinstein-Taybi patients 63
IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor 62
Effects of human recombinant type I IFNs (IFN-α2b and IFN-β1a) on growth and migration of primary endometrial stromal cells from women with deeply infiltrating endometriosis : a preliminary study 62
Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis 60
Efficacy of a novel second-generation somatostatin-dopamine chimera (TBR-065) in human medullary thyroid cancer: a preclinical study 58
Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro 57
β2 glycoprotein i recognition drives Th1 inflammation in atherosclerotic plaques of patients with primary antiphospholipid syndrome 57
The challenges of lupus anticoagulants 56
Chemerin serum levels in systemic sclerosis: a novel marker of early and active disease? 55
Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers 54
Obstetric and vascular APS : same autoantibodies but different diseases? 54
The story of the murine antiendothelial monoclonal antibody BGM. From patients' bedside to laboratory bench and from animal models to patients 54
Serum chemerin in systemic sclerosis : a novel marker of early diffuse disease? 54
Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series 54
Standardization of autoantibody testing : a paradigm for serology in rheumatic diseases 53
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors 53
In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions 51
Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies 51
Update on the pathogenesis and treatment of the antiphospholipid syndrome 51
Toll like receptors : a crossroad in scleroderma etiopathogenesis 50
Toll-like receptor 4 and β2 glycoprotein I interaction on endothelial cells 50
Improvement of lipoprotein functions related to cell cholesterol trafficking in rheumatoid arthritis patients treated with tocilizumab 49
Obstetric and vascular antiphospholipid syndrome: Same antibodies but different diseases? 46
Mechanisms of Action of the Antiphospholipid Antibodies 45
Enhanced liver fibrosis test: a further step toward depiction of fibrotic process in very early diagnosis of systemic sclerosis 44
Detection of early endothelial damage in patients with Raynaud's phenomenon 43
The Pathogenic Role of Immune Complexes Containing Scleroderma-Specific Autoantibodies in the Inductor Phase of the Disease 43
Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer 40
EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies 37
Totale 11.405
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.532
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.532
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.341 170 83 67 121 90 155 116 63 207 161 54 54
2020/20211.262 95 56 62 19 99 143 35 97 168 105 237 146
2021/20221.938 146 111 91 106 131 126 201 163 241 194 140 288
2022/20232.157 262 262 177 244 165 344 65 125 201 81 132 99
2023/20241.500 70 119 126 123 339 114 51 99 43 99 141 176
2024/202534 34 0 0 0 0 0 0 0 0 0 0 0
Totale 11.543